Literature DB >> 16794500

Treatment of retinoblastoma patients with chemoreduction plus local therapy: experience of the AC Camargo Hospital, Brazil.

Célia B G Antoneli1, Karina C B Ribeiro, Flávio Steinhorst, Paulo Eduardo R S Novaes, Martha M Chojniak, Marcio Malogolowkin.   

Abstract

To evaluate the efficacy of conservative management of intraocular retinoblastoma with chemoreduction combined with local therapy with or without plaque radiation in the preservation of the eye, and avoidance of external beam radiation therapy (EBRT) (success rate). From 1995 to 2000, 84 newly diagnosed patients with intraocular retinoblastoma were admitted to the Pediatric Department of the Hospital do Cancer A.C. Camargo, São Paulo, Brazil. All children were treated with 2 to 6 cycles of chemotherapy (carboplatin, vincristine, and etoposide) plus local therapy (cryotherapy, laser photocoagulation, and thermotherapy), or plaque radiation therapy during and/or after the chemotherapy. The Mann-Whitney test was used to compare means of quantitative variables. The chi test or the Fisher exact test were employed to verify the association between the outcome and the independent variables. For all tests alpha=5% was adopted. Success rate was higher for patients with bilateral tumors (54%) than for children with unilateral tumors (19%) (P=0.003). For patients with Reese-Ellsworth stages I, II, and III, no statistically significant differences in the success rates were noted in the group of unilateral (50%) and bilateral tumors (79.1%) (P=0.179). Among children with Reese-Ellsworth stages IV and V, the success rate was significantly higher for patients with bilateral tumors (40.7%) than for those with unilateral (0%) (P=0.012). Chemoreduction combined with local therapy, with or without plaque radiotherapy, is efficacious in avoiding enucleation and the use of external beam radiation therapy for children with intraocular retinoblastoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794500     DOI: 10.1097/00043426-200606000-00004

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  16 in total

1.  Long term follow-up results of external beam radiotherapy as primary treatment for retinoblastoma.

Authors:  Sang Yul Choi; Mi-Sook Kim; Sungyul Yoo; Chulkoo Cho; YoungHoon Ji; KumBae Kim; YoungSeok Seo; Kyung Duk Park; JunAh Lee; Tai-Won Lee
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

2.  Integrin-linked kinase regulates senescence in an Rb-dependent manner in cancer cell lines.

Authors:  Rose Duminuco; Jake W Noble; Joseph Goody; Manju Sharma; Bruce R Ksander; Calvin D Roskelley; Michael E Cox; Julia Mills
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  c-Jun N-terminal kinase is involved in the regulation of proliferation and apoptosis by integrin-linked kinase in human retinoblastoma cells.

Authors:  Zhen Chen; Anhuai Yang; Chong Xu; Yiqiao Xing; Wenrong Gong; Junping Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

4.  Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds.

Authors:  David H Abramson; Xunda Ji; Jasmine H Francis; Federica Catalanotti; Scott E Brodie; Larissa Habib
Journal:  Br J Ophthalmol       Date:  2018-06-06       Impact factor: 4.638

5.  Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation.

Authors:  Patricia Helena Pecora Liberman; Christiane Schultz; María Valéria Schmidt Goffi-Gómez; Célia B G Antoneli; Martha Motoro Chojniak; Paulo Eduardo Novaes
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

6.  Treatment with connexin 46 siRNA suppresses the growth of human Y79 retinoblastoma cell xenografts in vivo.

Authors:  Diana B Burr; Samuel A Molina; Debarshi Banerjee; Derek M Low; Dolores J Takemoto
Journal:  Exp Eye Res       Date:  2011-02-12       Impact factor: 3.467

Review 7.  Retinoblastoma: one world, one vision.

Authors:  Carlos Rodriguez-Galindo; Mathew W Wilson; Guillermo Chantada; Ligia Fu; Ibrahim Qaddoumi; Célia Antoneli; Carlos Leal-Leal; Tarun Sharma; Margarita Barnoya; Sidnei Epelman; Louis Pizzarello; Javier R Kane; Ray Barfield; Thomas E Merchant; Leslie L Robison; A Linn Murphree; Patricia Chevez-Barrios; Michael A Dyer; Joan O'Brien; Raul C Ribeiro; John Hungerford; Eugene M Helveston; Barrett G Haik; Judith Wilimas
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

Review 8.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Antonella D'Anneo; Giuseppa Augello; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Renza Vento
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

Review 10.  Survey on the management of orbital and intraocular tumors among oculofacial surgeons in the Asia-Pacific region.

Authors:  Priscilla Xinhui Wang; Victor Teck Chang Koh; Katherine Lun; Gangadhara Sundar
Journal:  Int Ophthalmol       Date:  2013-10-02       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.